Published in Hepatitis Weekly, May 17th, 2010
"PF-03491390 inhibits multiple caspases and lowers serum AST and ALT levels in patients with chronic liver diseases. To determine if treatment with an oral pancaspase inhibitor could reduce serum AST and ALT in patients with HCV. Double-blind, randomized, placebo-controlled, parallel-dose study in 204 patients treated with placebo or PF-03491390 (5, 25 or 50 mg) orally...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.